Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals

Indivior PLC (LSE/Nasdaq: INDV), a leading addiction treatment company, today announced that it has gained exclusive global rights to develop, manufacture,...

October 12, 2023 | Thursday | News
Hansa Biopharma announces encouraging high-level results for first-in-human trial of HNSA-5487

Hansa Biopharma, "Hansa", a pioneer in enzyme technology for rare immunological conditions,  announced high-level results from NICE-01, the first-in-h...

October 10, 2023 | Tuesday | News
Cytiva opens new manufacturing facility and experience center in India

According to Cytiva’s 2023 Global Biopharma Resilience Index, the manufacturing of biologics in India is likely to increase over the next three years...

October 06, 2023 | Friday | News
FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United States FDA approval is based on a robust analytical, non...

October 02, 2023 | Monday | News
X-Chem and Structural Genomics Consortium Partner to Unlock Human Proteome and Promote Open Science

The goal is to generate DNA-encoded library (DEL) screening data for large numbers of under-addressed proteins in the human proteome — ultimately all...

September 29, 2023 | Friday | News
Everest Medicines Secures Taiwan Approval for XERAVA® in Treating Complicated Intra-Abdominal Infections in Adults

"The NDA approval of XERAVA® in Taiwan marks an important step towards bringing this novel, critical therapy for complicated intra-abdominal infections...

September 28, 2023 | Thursday | News
Evozyne Raises $81M for AI-Driven Drug Discovery

Evozyne announced the closing of an $81 million Series B investment round that will fund the biotech’s generative AI-powered drug discovery platform ...

September 28, 2023 | Thursday | News
Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb

Amphista Therapeutics (“the Company” or “Amphista”), a leader in next generation targeted protein degradation (TPD) approaches, tod...

September 27, 2023 | Wednesday | News
Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®

“We are thrilled to receive marketing approval for AVT04 in Japan, which will be Alvotech’s second marketed biosimilar,” said Robert Wess...

September 26, 2023 | Tuesday | News
Japan Approves EPKINLYTM as First Bispecific Antibody for R/R LBCL

Subcutaneous EPKINLYTM (epcoritamab) is the first and only bispecific antibody approved in Japan to treat adult patients with certain types of relapsed/r...

September 26, 2023 | Tuesday | News
Valo Health and Novo Nordisk to Collaborate on AI-Driven Cardiometabolic Treatments

Novo Nordisk licenses three preclinical drug discovery programmes in cardiovascular diseases discovered and developed by Valo using the Opal Computational ...

September 26, 2023 | Tuesday | News
SK Pharmteco Expands with Controlling Stake in Center for Breakthrough Medicines

CBM brings extensive cell and gene therapy expertise to SK pharmteco portfolio and continues SK pharmteco’s strategy to deliver end-to-end, multi-mod...

September 21, 2023 | Thursday | News
European Commission Approves ORSERDU® for ER+ Breast Cancer with ESR1 Mutation

Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive disease¹; more tha...

September 14, 2023 | Thursday | News
Abbott Broadens Access to Cutting-Edge Biosimilars in Key Emerging Markets

Abbott to commercialize several biosimilar molecules in key emerging markets in Latin America, Southeast Asia, the Middle East and Africa Spain-based gl...

September 21, 2023 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close